2004
DOI: 10.1053/j.pcsu.2004.02.024
|View full text |Cite
|
Sign up to set email alerts
|

Heparin-induced thrombocytopenia (HIT) in pediatric cardiac surgery: an emerging cause of morbidity and mortality

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
54
0

Year Published

2005
2005
2023
2023

Publication Types

Select...
4
3

Relationship

0
7

Authors

Journals

citations
Cited by 53 publications
(54 citation statements)
references
References 50 publications
0
54
0
Order By: Relevance
“…It has been described in pediatric patients but may be less prevalent or less severe. [423][424][425][426] In patients with a recent history of HIT requiring cardiac surgery, alternatives to heparin may be necessary. Alternatives to heparin in pediatric patients undergoing operations with CPB include danaparoid and the direct thrombin inhibitors argatroban and bivalirudin.…”
Section: Hit and Alternatives To Heparin For Anticoagulation For Cpb mentioning
confidence: 99%
“…It has been described in pediatric patients but may be less prevalent or less severe. [423][424][425][426] In patients with a recent history of HIT requiring cardiac surgery, alternatives to heparin may be necessary. Alternatives to heparin in pediatric patients undergoing operations with CPB include danaparoid and the direct thrombin inhibitors argatroban and bivalirudin.…”
Section: Hit and Alternatives To Heparin For Anticoagulation For Cpb mentioning
confidence: 99%
“…6 However, orthopedic surgery patients, despite having a lower frequency of HIT antibodies, are more likely than cardiac surgery patients to develop HIT. 14 In cardiac surgery patients, the frequency of HIT in pediatrics (1.3%) 24 is generally comparable to that estimated in adults in combined-study analyses (Ϸ2.4%). 25 Prospective studies indicate that HIT occurs in Ϸ0.3% to 3% of medical patients receiving heparin therapy.…”
Section: Frequencymentioning
confidence: 69%
“…97 Limited data exist on the use of recombinant factor VIIa as a nonspecific antidote for treating severe bleeding in patients with HIT. 24,98 Symptomatic and supportive care should be given.…”
Section: Fondaparinuxmentioning
confidence: 99%
See 2 more Smart Citations